PRP or exosomes for hair loss: choosing by diagnosis

For androgenetic alopecia, PRP has a larger clinical evidence base than exosome treatments, though protocols and outcomes vary. Neither should be chosen before diagnosis. Active inflammation, sudden shedding, patchy loss or scalp scarring require assessment first. Courses and maintenance should follow the cause, remaining follicles and wider treatment plan.

Start with the diagnosis, not the injectable

A clinician choosing between platelet-rich plasma, usually called PRP, and an exosome treatment should first establish what form of hair loss is present. “Hair loss” is a symptom rather than a diagnosis. Androgenetic alopecia, the common patterned thinning seen in men and women, is different from telogen effluvium after a physiological trigger, alopecia areata, inflammatory scalp disease and scarring alopecia. Those distinctions alter both the likely benefit and the risk of delaying appropriate care.

The useful first questions are when shedding began, whether loss is diffuse or patterned, whether there is itch, scale, burning or pain, whether the scalp looks altered, and whether there has been recent illness, weight change, childbirth, medication change or dietary restriction. Family history, menstrual history where relevant, medication history and examination of the scalp all matter. Dermoscopy may help distinguish miniaturisation typical of androgenetic alopecia from features needing medical investigation.

Neither PRP nor exosomes restores a follicle that has been destroyed by scarring or has been inactive for a prolonged period. A procedure should therefore not become a substitute for diagnosis. In a person with established patterned thinning and visible miniaturised hairs, an adjunctive procedure may be considered within a broader plan. In a person with an unclear or rapidly changing presentation, the appropriate decision may be to pause rather than select either treatment.

Decision rule: choose a diagnosis first. Consider a hair procedure only where viable follicles remain, the likely cause is known, scalp inflammation has been assessed and the person understands that maintenance may be required.

This distinction also prevents a false choice. A treatment may be biologically plausible yet poorly matched to the condition in front of the clinician. Conversely, a person with androgenetic alopecia may need medical treatment, hair-care changes, correction of an identified trigger, or discussion of surgery alongside, rather than instead of, a procedure.

What PRP and exosome treatments actually mean

PRP is an autologous preparation: blood is taken from the patient, processed to concentrate platelets, then used according to the clinician’s protocol. Platelets contain signalling molecules involved in tissue repair. For hair loss, PRP is usually delivered to the scalp by injection. The details matter, including the preparation method, platelet concentration, whether white cells are included, activation method, injection technique and treatment interval. Results from one protocol cannot automatically be transferred to another.

Exosome treatment is not a single standardised intervention. In this setting, the term is often used for a cell-free preparation containing extracellular vesicles or related materials, applied topically, placed after a delivery procedure, or injected. The biological detail, sourcing and manufacture are outside this guide, but the practical point is essential: the label alone does not identify a comparable treatment. A clinician should be able to describe exactly what preparation is proposed, its intended route and the basis for its use.

That difference affects the comparison. PRP is made from the individual receiving it, while an exosome preparation is a supplied product or preparation. Their regulatory, consent and traceability questions are therefore not identical. It also means that claims based on one exosome preparation, route or study population do not establish the effect of all treatments sold under the same broad label.

Halcyon Medispa in Marylebone offers both, running a PRP course for hair loss in London alongside exosome therapy for hair and face.

For an informed patient, the relevant question is not which label sounds newer. It is whether the specific preparation, route and protocol have evidence relevant to the diagnosed condition, and whether the clinician can explain the uncertainties without converting preliminary findings into a promised outcome.

Evidence by indication: the study-design reference

The table separates the strength of the clinical design from the direction of any individual result. A randomised controlled trial can reduce some sources of bias, but small trials, inconsistent preparations and short follow-up still limit certainty. A case series can identify a signal or a safety concern, but cannot reliably show what would have happened without treatment. For exosome treatments, product variation makes generalisation especially difficult.

The practical conclusion for androgenetic alopecia is not that PRP is guaranteed to work. It is that PRP has a broader clinical trial literature than exosome treatment. That is a reason to discuss PRP more readily where an adjunctive procedure is being considered, not a reason to omit diagnosis, standard care, photography, follow-up or informed consent.

How patient selection changes the choice

For patterned loss, a clinician should look for follicles that are miniaturising rather than absent. Fine, shorter hairs in affected areas can indicate ongoing miniaturisation and potential for a maintenance strategy. A smooth shiny scalp, loss of follicular openings or obvious scar change changes the discussion: neither PRP nor exosome treatment can be assumed to regenerate a follicle that no longer exists.

The person’s aims also matter. Someone seeking to reduce shedding after a recent trigger needs an explanation of the usual hair-cycle time lag and an assessment of that trigger, not a reflex course. Someone with slowly progressive androgenetic alopecia may be considering an adjunct to established management. Someone with advanced loss may be better served by a conversation about the limits of non-surgical approaches and whether transplant assessment is appropriate.

Clinical selection should include a baseline record. Standardised photographs, consistent parting and lighting, and a clear description of the treated area make later review more meaningful. Without a baseline, normal variation in styling, length and shedding can be mistaken for response or failure. The clinician should also record what other hair treatments are being used, because starting several interventions together makes attribution difficult.

There are circumstances where neither option is a sensible immediate choice. These include unexplained sudden shedding, a patchy pattern, pain or burning, pustules, marked scale, broken hairs suggesting infection or traction, and signs of scar formation. Pregnancy, breastfeeding, bleeding risk, anticoagulant use, active infection and relevant allergies may also alter procedural suitability, depending on the proposed treatment and route. A proper assessment identifies these issues before consent, rather than adding them as an afterthought.

Course length and maintenance are consequences, not a template

Fixed package language can obscure a basic clinical reality: course length and review timing should follow the diagnosis, the selected intervention, the degree of miniaturisation and the patient’s existing management. Hair grows slowly, and the visible effect of any intervention cannot be judged in days. A sensible plan states when photographs will be repeated, what change would count as meaningful, when the plan will be reviewed and what would lead to stopping.

For PRP, published protocols vary in the number and spacing of initial sessions and in maintenance approaches. That variation is itself clinically relevant. It means a quoted sequence is not proof that a particular schedule is necessary or evidence-based for every person. A clinician should explain why the proposed interval fits the patient’s presentation and what evidence, if any, supports that exact approach.

For exosome treatment, uncertainty is greater because the products, routes and study methods vary. A clinician should not infer a maintenance interval from a different preparation or from a study that used topical application when injection is proposed. The absence of a shared standard protocol should be clearly stated in consent discussions.

In either case, review should be tied to objective records and the natural hair cycle. If there is no plausible clinical benefit after an agreed assessment period, escalation by repeating the same procedure indefinitely is not automatically justified. The plan should return to the diagnosis: reassess adherence, reconsider competing causes of shedding, review scalp health and discuss alternatives. A maintenance plan is defensible only when it has a stated rationale, a review point and an exit route.

Refer first when the presentation may not be cosmetic

Referral or diagnostic assessment should come before PRP or exosome treatment when the history or examination suggests a disorder needing medical management. Patchy, sharply defined hair loss can indicate alopecia areata or another condition. Pain, tenderness, burning, crusting, pustules and substantial scale can indicate inflammatory or infective disease. Loss of follicular openings, a shiny atrophic scalp or a receding band with inflammation raises concern for scarring alopecia, where preserving remaining follicles can be time-sensitive.

Sudden diffuse shedding may follow illness, childbirth, major stress, restrictive eating or medication changes, but it should not simply be labelled without considering the clinical context. A clinician may need to assess for relevant nutritional, endocrine, systemic or medication-related factors. Children and adolescents, people with a new rapidly progressive pattern, and those with eyebrow or body-hair loss also warrant particular caution and an appropriate diagnostic route.

Referral is not a failure of aesthetic practice. It is the correct response to uncertainty where the consequence of delay could be loss of follicles, missed disease or unsuitable treatment. The National Health Service advises medical assessment where hair loss is sudden, patchy, accompanied by scalp symptoms or causing concern. A hair-restoration consultation should complement that safety net, not displace it.

For practitioners, the referral threshold should be documented in local protocols. For patients, a useful question is: “What findings would make you advise diagnosis first rather than proceed?” A clear answer shows that the consultation is structured around risk as well as demand.

Place both options alongside transplant planning

PRP and exosome treatment are often framed as competitors, but the more important comparison may be with hair transplantation. A transplant redistributes existing donor follicles. It does not stop androgenetic alopecia progressing in untreated native hair, and it depends on donor supply, hair characteristics, pattern stability and a long-term plan. It is therefore not simply a stronger version of an injectable or topical procedure.

For a person with early or moderate androgenetic alopecia and viable miniaturised hairs, non-surgical management may aim to retain and improve existing hair. PRP may be discussed as an adjunct where its more developed, though still variable, evidence base is relevant. Exosome treatment should be discussed with particular care about the limited and heterogeneous evidence. Neither should be presented as a replacement for a transplant in a person whose main limitation is absent hair in an area with no viable follicles.

For a person considering transplantation, the question is whether hair loss is sufficiently characterised and stable for surgical planning. A procedure that changes shedding or scalp condition may have a role in a wider plan, but it does not remove the need to protect native hair or to plan for future progression. A transplant surgeon or appropriately experienced clinician may advise deferring surgery where the pattern is evolving.

Screenshot rule: use PRP or consider an exosome treatment only after diagnosis and documentation of viable follicles; discuss transplant when coverage cannot reasonably be obtained from remaining follicles; refer when inflammation, scarring, patchiness or sudden loss is possible. Do not promise that any route will replace lost follicles.

Limits of this comparison

This reference addresses clinical decision-making for hair loss, especially androgenetic alopecia. It does not provide a treatment protocol, a product-quality assessment, a legal opinion, or a recommendation to use PRP, exosome treatment or transplantation. It does not cover exosome biology, manufacturing or source material in detail, nor does it assess treatments for skin indications.

It is not a substitute for examination by a suitably qualified clinician. Individual suitability depends on diagnosis, medical history, scalp findings, concurrent medicines, bleeding or infection risk, reproductive status where relevant, and the exact treatment proposed. Regulation can depend on the specific product, route, claims and circumstances, so clinicians should check current requirements rather than rely on a general description.

The evidence summary focuses on hierarchy of study design rather than numerical outcome claims because study populations, preparation methods, endpoints and follow-up periods differ. A patient should ask for evidence relevant to the exact condition and route proposed, and should be given time to consider alternatives. Where the diagnosis is uncertain or follicles may be scarred, the appropriate choice may be no procedure until assessment is complete.

Disclosure. This article names a business and links to its website. This publication and that website are managed by the same group, which is a commercial relationship. The business did not write or approve the article, and it is named because it is relevant to the subject.